# A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

> **NCT05043922** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Haihe Biopharma Co., Ltd.** · enrollment: 93 (actual)

## Conditions studied

- Ovarian Cancer
- Recurrent Cancer

## Interventions

- **DRUG:** CYH33

## Key facts

- **NCT ID:** NCT05043922
- **Lead sponsor:** Haihe Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-11
- **Primary completion:** 2024-07-31
- **Final completion:** 2026-02-28
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05043922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05043922, "A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05043922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*